Phase I Study of Isotretinoin in Patients With Recessive Dystrophic Epidermolysis Bullosa
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00014729|
Recruitment Status : Completed
First Posted : April 11, 2001
Last Update Posted : March 25, 2015
I. Determine the safety of isotretinoin in patients with recessive dystrophic epidermolysis bullosa.
|Condition or disease||Intervention/treatment||Phase|
|Epidermolysis Bullosa||Drug: isotretinoin||Phase 1|
Patients receive oral isotretinoin daily for 8 months in the absence of disease progression or unacceptable toxicity.
Completion date provided represents the completion date of the grant per OOPD records
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Study Start Date :||October 2000|
|Estimated Study Completion Date :||September 2002|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00014729
|Study Chair:||Jo-David Fine||University of North Carolina|